I’m not sure how it started, but Frank Dolan and I were having a conversation and I became curious about disease state education. Who would attend and why? What are the benefits for a company about to launch a new product? And what might this look like in a virtual world?
This podcast conversation was in the context of biopharma but it is relevant for all of life sciences.
Disease state education is content marketing plain and simple.
Before a brand (new drug) is approved you can’t talk about it or make any claims. That doesn’t stop you from growing an audience to build trust and credibility for your company.
Whether you are a biotech launching your first drug or a startup instrument manufacturer struggling for awareness, gathering experts to talk about the disease state or state-of-the-art is an opportunity to be recognized and learn about your potential customers.
EVENTS:
Medicine to Market Summit: Brand Breakthroughs
Live Webinar: Life Science Marketing
Schedule a 15 minute chat with Chris about content.
Disease State Education: Content Marketing Pre-Launch